The reiteration of an Outperform rating and the maintenance of a $20 price target by a reputable analyst like Robert Driscoll from Wedbush could lead to increased investor confidence in IGM Biosciences. This positive analyst coverage is likely to have a favorable impact on the stock's short-term price movement, as it reaffirms the company's potential for growth and value.